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ORIGINAL ARTICLE
PTEN Promoter Hypermethylation Is Associated with 
Breslow Thickness in Acral Melanoma on the Heel, 
Forefoot, and Hallux
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Background: Acral melanoma occurs on glabrous skin or the 
nail apparatus and is distinct from ultraviolet-related melano-
ma due to differing genetic alteration patterns. Although the 
pathogenesis of acral melanoma is not well understood, me-
chanical stress is thought to induce acral melanoma. The in-
cidence of gene mutation and promoter methylation has 
been reported in tumors from acral melanoma; however, an 
association between genetic/epigenetic alterations and me-
chanical stress in acral melanoma remains unclear. Objec-
tive: To investigate the relationship between clinical/genetic 
factors and mechanical stress in acral melanoma. Methods: 
A retrospective review of 52 patients diagnosed with acral 
melanoma was performed. We reviewed the clinical charac-
teristics of patients, tumor status, and tumor location. Muta-
tions in BRAF, NRAS, and the TERT promoter, along with KIT 
amplification and PTEN promoter methylation were ana-
lyzed in the tumors. Results: The heel (34/52, 65.4%) was the 
most common anatomical tumor site. Mutations in BRAF 
(6/48, 12.5%), NRAS (6/49, 12.2%), and the TERT promoter 
(4/33, 12.1%), along with KIT amplification (3/37, 8.1%) and 
PTEN promoter hypermethylation (12/48, 25.0%) were ob-
served in the tumors. On the forefoot, heel, and hallux, PTEN 
promoter hypermethylation was significantly associated 
with Breslow thickness (p=0.001) and ulceration rate (p= 
0.042). On the midfoot and lesser toes, there was no sig-
nificant difference in Breslow thickness or ulceration rate re-
gardless of PTEN promoter hypermethylation (p＞0.05). Con-
clusion: PTEN promoter hypermethylation is associated with 
Breslow thickness and tumor ulceration on the forefoot, heel, 
and hallux in acral melanoma in Korean patients. (Ann 
Dermatol 33(1) 18∼25, 2021)
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INTRODUCTION
Cutaneous melanoma, which is a heterogeneous group of 
tumors, is subdivided into four types: chronic sun dam-
age-induced melanoma (CSD), non-CSD, mucosal mela-
noma, and acral melanoma1. Among them, acral melano-
ma occurs on glabrous skin or the nail apparatus and is 
distinct from ultraviolet (UV)-related melanoma due to dif-
fering genetic alteration patterns2,3. Acral melanoma most-
ly displays histologic features of acral lentiginous melano-
ma (＞80%)4. Acral melanoma accounts for 2% to 8% of 
melanomas in Caucasians, whereas it accounts for more 
than 40% of melanomas in Asians5. Acral melanoma is the 
most common type of melanoma in the Korean popula-
tion4.
Melanoma is one of cancer that harbors the highest so-
matic mutational burdens among all solid malignancies6. 
Acral melanoma is genetically distinct from other cuta-
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Fig. 1. Anatomical mapping of gene-
tic and epigenetic alterations in acral 
melanoma on the glabrous foot. 
Heel, forefoot, and hallux are yellow- 
colored and the centers of the le-
sions are plotted (n=52). Each dot 
is color-coded according to the muta-
tion type (A) or PTEN promoter hy-
permethylation (B). (C) Both muta-
tions and PTEN promoter hyperme-
thylation are shown in each dot.
neous melanomas. Molecular genetics research has dem-
onstrated several mutational differences between UV-re-
lated melanoma and non-UV related melanoma. Acral 
melanomas have a low mutational burden, differing mu-
tated genes, and a differing type of genetic alteration3. 
UV-related mutational signatures, C＞T or CC＞TT, are 
typically not detected in acral melanomas2. BRAF muta-
tions (14.8%) and NRAS mutations (13.3%) are less fre-
quently observed in acral melanomas than in other cuta-
neous melanomas (45%∼60% and 15%∼25%)7. TERT 
promoter mutations are reported in 33%∼65% of cuta-
neous melanomas, but in less than 10% of acral melano-
mas8. Acral melanomas show recurrent genomic copy 
number alterations, which include gains of TERT (5p15), 
KIT (4q12), CCND1 (11q13), and AURKA (20q13)2. These 
results suggest that acral melanomas may have different 
genetic causal pathways than UV-related melanomas9. 
Besides genetic alterations, a recent study had reported 
that epigenetic alterations, such as RARB and PTEN pro-
moter hypermethylation, are prognostic markers in cuta-
neous melanoma10. Although promoter hypermethylation 
frequency is lower in tumors from Asian individuals than 
in tumors from Caucasian individuals, PTEN promoter hy-
permethylation has been shown to be an independent 
prognostic factor for survival for melanoma in Asian pop-
ulations11. However, the clinical significance of promoter 
methylation and somatic mutation in acral melanoma is 
unclear.
Besides genetic factors, other factors, such as mechanical 
stress, are considered factors for non-UV related melano-
ma12-14. Several reports have shown a high incidence of 
acral melanomas on the weight-bearing portion of the 
sole15-17, and more oral mucosal melanomas have occurred 
on the hard palatal mucosa and maxillary gingiva than on 
other areas of the oral mucosal surface14. From studies on 
sole pressure while standing and walking18,19, the heel and 
forefoot showed the highest peak pressures. The little toes 
and midfoot are relatively low-pressure areas. Also, recent 
studies have shown that more acral melanomas occur on 
the heel than on any other areas of the plantar surface12,13. 
Based on the relationship between acral melanoma and 
pressure, we investigated whether there are genetic or cli-
nical factors associated with pressure. We evaluated muta-
tions in BRAF, NRAS, and in the TERT promoter, along 
with KIT amplification and PTEN promoter hypermethyla-
tion in primary tumors on the plantar surface in Korean ac-
ral melanoma patients. We assessed the association of 
these genetic/epigenetic alterations with tumor status, me-
chanical stress, and clinical characteristics.
MATERIALS AND METHODS 
This study included 52 acral melanoma patients. A retro-
spective review of 52 patients diagnosed with acral mela-
noma was carried out. Medical records and mutation anal-
ysis results were reviewed from acral melanoma patients 
who were treated at Severance Hospital and Yonsei 
Cancer Hospital from 2002 to 2012. We selected 52 pa-
tients with genetic and epigenetic alteration results for 
analysis. Clinical data that included age, sex, body mass 
index, tumour-node-metastasis stage, Breslow thickness, and 
ulceration (both macroscopic and microscopic) were col-
lected. From the genetic and epigenetic alteration results, 
mutations in BRAF, NRAS, and the TERT promoter, along 
with KIT amplification and PTEN promoter hypermethyla-
tion were reviewed. This retrospective study was approved 
by the Institutional Review Board of Gangnam Severance 
Hospital (IRB no. 2019-0487-001). The requirement of in-
formed consent was exempted.
All lesions with clinical pictures were standardized as a 
composite image and plotted by location according to 
pressure (Fig. 1). We divided the sole into 4 regions (heel, 
midfoot, forefoot, and toes), and each region was sub-
divided into various areas (center, medial, lateral, lesser 
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Table 1. Primers used in referred studies
Gene Exon Sequence















  promoter R: 5’-Biotin-CTCCCAGTGGATTCGCGGGC-3’
S: 5’-AGGGGCTGGGAGGGC
KIT 17 F: 5’-AAAGATTTGTGATTTTGGTCTAGC-3’
R: 5’-GAAACTAAAAATCCTTTGCA-3’
GAPDH 2 F: 5’-CACTAGGCGCTCACTGTTCT-3’
R: 5’-GCGAACTCACCCGTTG-3’
PTE F: 5’-GGATGTGGGTGTTTGTGTAATTA-3’
  promoter R: 5’-biotin-AATTCCCACTCCCCAATAATAA
C-3’
S: 5’-TTTGTGTAATTAGTTTTTTA-3’
F: forward primer, R: reverse primer, S: sequencing primer, GAPDH:
glyceraldehyde-3-phosphate dehydrogenase.
toes, hallux) based on previous pedobarographic pressure 
studies18-20. The forefoot included the metatarsal lesion 
and transverse arch. The midfoot included the cuboid 
bone and the medial and lateral arches. The heel included 
the calcaneus and talus bones. From previously published 
literature15-17 and in consideration of pedobarographic 
pressure20 and the 3 arches (2 longitudinal and 1 trans-
verse), we divided plantar foot into two areas (heel, fore-
foot, hallux vs. midfoot, lesser toes) (Fig. 1). The staging 
was determined according to the American Joint Committee 
on Cancer (AJCC) 8th guidelines for melanoma. 
DNA preparation and mutation analysis were performed 
as previously described21,22. Formalin-fixed, paraffin-em-
bedded tissue blocks diagnosed as acral melanoma were 
retrieved. Exon 15 (codon 600) of the BRAF gene and 
exons 1 and 2 (codon 12, 13, and 61) of the NRAS gene 
were amplified by polymerase chain reaction (PCR) in or-
der to detect hotspot mutations. PCR amplification of the 
TERT promoter region was also performed. The primer se-
quences are listed in Table 1. Pyrosequencing using a 
PyroMark Q24 (Qiagen, Germantown, MD, USA) was per-
formed at room temperature. Gold Q24 Reagents (Qiagen) 
were used according to the manufacturer’s instructions. 
Sequencing analysis was performed using PyroMark Q24 
software ver. 1.0.10 (Qiagen) in allele quantification anal-
ysis mode.
KIT amplification was analyzed as previously described21. 
KIT copy number was assessed by quantitative real-time PCR 
using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
as the control gene (KIT exon 17 and GAPDH primers are 
listed in Table 1). PCR reactions were performed in the 
Rotor-Gene 2000 Real-Time Cycler (Corbett Research, Mort-
lake, Australia) using the QuantiTect SYBR Green PCR Kit 
(Qiagen) with a 20 μl total volume and 100 ng of ge-
nomic DNA. Relative copy numbers were calculated by 
the ΔΔCt method, where Ct is the threshold cycle for 
amplification. For each sample, ΔCt for KIT vs. GAPDH 
was calculated as ΔCt=Ct (KIT)–Ct (GAPDH). The ΔCt 
value for each experimental test sample was calibrated to 
a reference pool of human genomic DNA (Promega, Madison, 
WI, USA) using the formula ΔΔCt=ΔCt (test sample)–Δ
Ct (reference pool). Relative DNA copy number was cal-
culated using the formula 2−ΔΔCt.
PTEN promoter methylation was analyzed as previously 
described11. Five potential promoter regions, spanning 
1,333 base pairs upstream and 1,297 base pairs down-
stream of the PTEN gene transcription start site, were ana-
lyzed. CpG islands were identified within the core pro-
moter region. For primer design, DNA sequences were 
converted in silico to the methylated form of CpG as fol-
lows: CG motifs were converted to YG with Y equalling 
either C/T or G/A, and then C was converted to T. Using this 
converted sequence, methylation-specific primers for quan-
titative sequencing (pyrosequencing) of PTEN CpGs were 
designed using the Biotage Assay Design software (Pyro-
Mark Assay Design 2.0) and the pyrosequencer PyroMark 
Q24 version 1.0.10 software (Qiagen). The primer se-
quences are listed in Table 1. Fifty nanogram of bisulfite- 
treated DNA was used in the PCR reaction with 200 
nmol/L forward and reverse primers. PCR conditions for 
PTEN were 95oC for 15 minutes; 50 cycles of 95oC for 40 
seconds, 55oC for 40 seconds, and 72oC for 40 seconds; 
and 72oC for 10 minutes. PCR reactions included 0.5 U of 
Amplitaq Gold (Applied Biosystems, Austin, TX, USA). 
The percentage methylated fraction (C/T ratio) was auto-
matically calculated. Each site was analyzed as a C/T poly-
morphism where a 100% C-reading denotes a fully methy-
lated C in the original genomic DNA sample, and a 100% 
T-reading denotes that the C was unmethylated in the ge-
nomic DNA sample. Intermediate C/T percentages denote 
partial methylation in the sample. The methylation values 
were calculated as the peak height methylated/(peak 
height methylated+peak height unmethylated)×100.
All statistical analyses were performed using SPSS ver. 
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Table 2. Baseline clinical characteristics of acral melanoma patients
Variable Total





Patient 52 (100.0) 43 (82.7) 9 (17.2)
Median age, yr (range) 65 (37∼89) 63 (37∼89) 67 (37∼80) 0.341
Female sex 26 (50.0) 22 (51.2) 4 (44.4) 0.725
BMI, kg/m2 (n=51) 24.04±3.14 24.36±2.85 22.37±3.90 0.675
  ≤23 20 15 (35.7) 5 (55.6)
  23＜BMI≤25 10 9 (21.4) 1 (11.1)
  ＞25 21 18 (42.9) 3 (33.3)
Ulceration (n=43) 0.071
  Yes 17 16 (47.1) 1 (11.1)
  No 26 18 (52.9) 8 (88.9)
Thickness, mm (n=48) 2.99±2.93 3.34±3.15 1.37±0.93 0.088
Gene alteration 
  BRAF (n=48) 6 (12.5) 5 1
  NRAS (n=49) 6 (12.2) 5 1
  TERT promoter (n=33) 4 (12.1) 4 0
  KIT amplification (n=37) 3 (8.1) 3 0
  PTEN promoter 
  hypermethylation (n=48)
12 (25.0) 11 1
Values are presented as number (%), mean (range), mean±standard deviation, or number only.
23.0 software (IBM Corp., Armonk, NY, USA). Categorical 
data were described using frequencies and percentages. 
Continuous data, such as age, were described using mean± 
standard deviation or median (range) for normally distri-
buted data. A chi-square test or Fisher exact test was used 
to differentiate the rates of different groups. Differences in 
measurement data between two groups were evaluated by 
unpaired t-test or Mann–Whitney test. Hierarchical cluster-
ing was performed to identify PTEN promoter “hyperme-
thylated” and “hypomethylated” samples. All statistical an-




Fifty-two acral melanoma patients were analyzed (Table 2). 
There were 26 males and 26 females with a sex ratio of 
1:1. The median age was 65 years (range, 37∼89 years). 
Ulceration was present in 17 patients (39.5%), with a mean 
Breslow thickness of 2.99 mm. There was no significant 
relationship between high body mass index (BMI) and ac-
ral melanoma on the heel, forefoot, and hallux (p＞0.05; 
Table 2). The mutation rate was 12.5% for BRAF (6/48), 
12.2% for NRAS (6/49), and 12.1% for the TERT promoter 
(4/33). The gene amplification rate for KIT was 8.1% (3/37). 
PTEN promoter hypermethylation (12/48) was also ob-
served in 25.0% of patients. The center of each acral mel-
anoma lesion was plotted on the composite image. Each 
dot is color-coded according to the gene alteration type 
(Fig. 1A) or PTEN promoter hypermethylation (Fig. 1B). All 
BRAF mutations (n=6) were BRAF V600E. In the 6 pa-
tients with NRAS mutations, a mutation in codon 61 was 
identified in 2 patients. In the other four patients, muta-
tions resulting in G12R in one patient and G13R in 3 pa-
tients were also detected. A G＞A transition in the TERT 
promoter was found at position −124 bp (relative to the 
ATG start site) in 4 patients.
Anatomical mapping of acral melanoma 
Among the 52 patients, the vertical distribution of lesions 
were as follows: 34 lesions (65.4%) on the heel, 4 lesions 
(7.7%) on the midfoot, 9 lesions (17.3%) on the forefoot, 
and 5 lesions (9.6%) on the toes. The heel (n=34, 65.4%) 
was the most common site. The parallel distribution of le-
sions was as follows: 12 lesions (23.1%) on the medial 
side, 14 lesions (26.9%) on the lateral side, and 26 lesions 
(50.0%) in the central region. The anatomic mapping of 
site distribution is shown in Fig. 1C. 
Analysis of the relationship between clinical/genetic 
factors and pressure
To analyze the relationship with pressure, the foot was 
divided into a pressure prone area and a lesser pressure 
prone area. Heel, forefoot, and hallux are yellow-colored 
on Fig. 1. We also analyzed the relationship between clin-
ical/genetic factors and pressure. Mutations in BRAF, NRAS, 
and the TERT promoter and KIT amplification profiles showed 
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Table 3. Genetic alteration profiles associated with Breslow thickness and ulceration in acral melanoma
Category
BRAF NRAS KIT amplification TERT promoter
Yes No Yes No Yes No Yes No
Heel, forefoot, hallux
  Breslow thickness 
    ≤1 1 (20.0) 9 (27.3) 0 10 (29.4) 0 9 (33.3) 1 (33.3) 7 (28.0)
    ＞1.0∼2.0 1 (20.0) 10 (30.3) 1 (25.0) 10 (29.4) 2 (50.0) 6 (22.2) 1 (33.3) 2 (8.0)
    ＞2.0∼4.0 0 6 (18.2) 2 (50.0) 4 (11.8) 0 2 (7.4) 0 6 (24.0)
    ＞4 3 (60.0) 8 (24.2) 1 (25.0) 10 (29.4) 1 (66.6) 10 (37.0) 1 (33.3) 10 (40.0)
    p-value 0.239 0.295 0.325 0.543
  Ulceration
    Yes 2 (66.7) 13 (43.3) 2 (50.0) 13 (44.8) 2 (66.6) 10 (43.5) 0 11 (52.4)
    No 1 (33.3) 17 (56.7) 2 (50.0) 16 (55.2) 1 (25.0) 13 (56.5) 2 (100.0) 10 (47.6)
    p-value 0.579 ＞0.999 0.425 0.478
Midfoot, lesser toes
  Breslow thickness 
    ≤1 0 4 (50.0) 0 4 (50.0) 0 3 (50.0) 0 0
    ＞1.0∼2.0 0 2 (25.0) 1 (100) 1 (12.5) 0 2 (33.3) 0 3 (75.0)
    ＞2.0∼4.0 1 (100) 2 (25.0) 0 3 (37.5) 0 1 (16.7) 0 1 (25.0)
    ＞4 0 0 0 0 0 0 0 0
    p-value 0.222 0.556 NA NA
  Ulceration 
    Yes 0 1 (12.5) 0 1 (12.5) 0 0 0 0
    No 1 (100) 7 (87.5) 1 (100) 7 (87.5) 1 (100) 6 (100) 1 (100) 4 (100)
    p-value ＞0.999 ＞0.999 NA NA
Values are presented as number (%).
Table 4. PTEN promoter hypermethylation associated with Bre-





  Breslow thickness 0.001*
    ≤1 0 9 (33.3)
    ＞1.0∼2.0 1 (11.1) 8 (29.6)
    ＞2.0∼4.0 0 6 (22.2)
    ＞4 8 (88.9) 4 (14.8)
  Ulceration 0.042*
    Yes 6 (75.0) 7 (30.4)  
    No 2 (25.0) 16 (69.6)
Midfoot, lesser toes
  Breslow thickness 0.556
    ≤1 0 2 (25.0)
    ＞1.0∼2.0 0 4 (50.0)
    ＞2.0∼4.0 1 (100) 2 (25.0)
    ＞4 0 0
  Ulceration 0.125
    Yes 1 (100) 0
    No 0 7 (100)
Values are presented as number (%). *Statistically significant (p＜
0.05).
no association with Breslow thickness or ulceration rate 
on both groups (p＞0.05; Table 3). However, PTEN pro-
moter hypermethylation showed an association with Bre-
slow thickness (p=0.001; Table 4) and ulceration (p= 
0.042; Table 4) on the heel, forefoot, and hallux. In the 
presence of PTEN promoter hypermethylation, Breslow 
thickness was increased only on the heel, forefoot, and 
hallux. In the midfoot and lesser toes, there were no sig-
nificant differences in Breslow thickness or ulceration rate 
associated with PTEN promoter hypermethylation (p＞0.05; 
Table 4).
DISCUSSION
In the present study, we investigated whether there are ge-
netic or clinical factors associated with pressure in Korean 
acral melanoma patients. We discovered that PTEN pro-
moter hypermethylation was associated with foot melano-
ma thickness and ulceration rate only on the heel, fore-
foot, and hallux. We found that 25.0% of acral melanoma 
patients had PTEN promoter hypermethylation. The hyper-
methylation rate (12/48, 25.0%) of Korean acral melano-
ma patients is consistent with the rate found in a previous 
Korean study (31/158, 19.6%)11. We checked the associa-
tion between PTEN promoter hypermethylation and Breslow 
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thickness, and there was no significant correlation (p= 
0.238), which is also consistent with the previous study11.
Somatic mutation rates of acral melanoma patients were also 
similar to other studies23. No other somatic alterations (mu-
tations in BRAF, NRAS, and the TERT promoter, KIT am-
plification) were associated with Breslow thickness or ul-
ceration rate in acral melanoma. These results are consis-
tent with an analysis of 48 cases of acral melanoma in 
Brazil23. 
Recently, several studies have suggested that mechanical 
stress is a possible factor in promoting acral melanoma, 
particularly on the sole24. Several reports have shown a 
high incidence of acral melanoma on the weight-bearing 
portion of the soles15-17,25. Sheen et al.25 recently showed 
that acral melanomas tended to develop on weight-bear-
ing areas, and the distribution pattern was not associated 
with clinical and prognostic factors. Our study show that 
heel (34/52, 65.4%) was the most common anatomical 
site of tumors and there was no significant relationship be-
tween high pressure area and other clinical factors (sex, 
age, BMI, Breslow thickness, ulceration), which is con-
sistent results with previous study25. 
We aimed to evaluate the role of long-term mechanical 
stress in acral melanoma by analyzing clinical and genetic 
factors on the heel, forefoot, and hallux. There was no sig-
nificant difference in Breslow thickness or ulceration rate 
on the heel, forefoot and hallux compared to the midfoot 
and lesser toes. Our data showed that tumor thickness and 
ulceration rate were only related to PTEN promoter hyper-
methylation on the heel, forefoot, and hallux. 
There are various types of mechanical stresses, which in-
clude pressure, friction, shearing forces, and stretching24. 
The relationship between mechanical stress and disease 
has been studied in Hidradenitis suppurativa, callus, and 
diabetic foot ulcers, but little has been reported in acral 
melanoma. Friction primarily applies to the epidermis, which 
causes intertrigo and hidradenitis suppurativa26, whereas 
shear injury affects deeper skin layers and causes pressure 
ulcers. Shear stress is defined as force per unit area ex-
erted parallel to the sole plane while walking27. When 
standing, the pressure acts perpendicular to the plane and 
extends across the entire skin layer (epidermis, dermis, 
subcutaneous tissue)24. In acral melanoma patients, stand-
ing pressure and shear stress mainly affect the foot.
Physiologically, shear stress elicits an increase in cuta-
neous microvascular reactivity and endothelial function27. 
In the tumor microenvironment, shear stress activates trans-
forming growth factor-β (TGF-β) signalling, inducing the 
epithelial to mesenchymal transition28. TGF-β signalling, 
which is associated with tissue fibrosis and the tumor mi-
croenvironment have predominant roles by stimulating 
the non-canonical hedgehog pathway in the epithelial-me-
senchymal transition. This stimulation is important in mel-
anoma invasion and metastasis. However, how macro-
scopic mechanical forces regulate cell fate through genet-
ic/epigenetic alterations remains unclear in acral melanoma. 
Further prospective investigation of mechanical stress and 
genetic/epigenetic alterations will be needed.
PTEN, a tumor-suppressor gene, is implicated in cellular 
differentiation, reproduction, and apoptosis, as well as in 
cellular adhesion and mobility. Multiple studies have shown 
reduced, but not absent, PTEN in melanoma29,30. Recent 
studies have shown that complete or partial loss of PTEN 
in melanoma is associated with poor overall survival31,32. 
However, PTEN loss cannot be fully explained by genetic 
alteration. In the New York University and the Cancer Ge-
nome Atlas (TCGA) melanoma cohorts, PTEN mutations and 
deletions were relatively uncommon in melanoma32. PTEN 
promoter hypermethylation has also been associated with 
loss of PTEN in melanoma. In the TCGA and Korean mela-
noma cohorts, PTEN promoter methylation was a signifi-
cant negative prognostic marker of survival for melanoma 
patients7,11. Our study showed that PTEN promoter meth-
ylation is associated with increased Breslow thickness and 
higher ulceration rates in acral melanomas. This result was 
limited to the heel, forefoot, and hallux. Based on these 
clinical results, additional studies will be needed to inves-
tigate whether epigenetic alterations of PTEN, such as hy-
per- or hypomethylation and histone modifications, are as-
sociated with PTEN loss in acral melanoma. In selected 
acral melanoma patients, induction of tumor PTEN ex-
pression above a threshold level might suppress Akt activ-
ity and tumor growth and promote anti-tumor immunity to 
improve patient survival33.
There are a number of limitations of this study. First, as a 
retrospective single-center study, the sample size is small. 
Further large-scale and population-based analysis contain-
ing more samples, especially on midfoot and lesser toes, is 
needed to clearly show the relationship between mechan-
ical stress and genetic/epigenetic alterations. Second, the 
methodology used to analyze weight bearing area was dif-
ferent from other studies. However, there is no study clar-
ifying where is weight bearing area of sole. In this study, 
sole was divided into two parts considering pedobarog-
raphy results of non-melanoma patients while walking and 
standing. In future study, measuring pedobarography of 
acral melanoma patients may help to consider not only 
weight bearing portion of sole, but also the external pres-
sure details such as personal walking habits, pressure 
caused by shoes, and pressure when lying down during 
sleep.
In conclusion, we have characterized genetic/epigenetic 
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alterations and the relationship with pressure in 52 acral 
melanoma patients. We have shown that about 25% of ac-
ral melanoma patients harbor PTEN promoter hypermethyl-
ation. Moreover, epigenetic alterations, like PTEN promoter 
hypermethylation, are related to increased Breslow thick-
ness and higher ulceration rates on the heel, forefoot, and 
hallux in acral melanoma patients. These results could 
help identify the possible role of mechanical stress in pro-
moting acral melanoma. Further prospective investigation 
of molecular alterations will be needed to understand the 
relationship between mechanical stress and genetic/epi-
genetic alterations. 
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